Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | TYR | P14679 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001354 | 1.00 | CYP1A2 (0.75) | CYP1A2TRPV1HCAR2CA12AKR1B10 | |
| SCHEMBL818742 | 1.00 | CYP1A2 (0.75) | CYP1A2TRPV1HCAR2CA12AKR1B10 | |
| SCHEMBL4805633 | 0.94 | CYP1A2 (0.68) | CYP1A2TRPV1HCAR2CA12AKR1B10 | |
| SCHEMBL6570565 | 0.88 | HCAR2 (0.59) | CYP1A2TRPV1HCAR2CA12AKR1B10 | |
| SCHEMBL5573179 | 0.87 | CYP1A2 (0.62) | CYP1A2TRPV1HCAR2CA12AKR1B10 | |
| SCHEMBL5573185 | 0.87 | CYP1A2 (0.62) | CYP1A2TRPV1HCAR2CA12AKR1B10 | |
| SCHEMBL26382466 | 0.86 | CYP1A2 (1.00) | CYP1A2TRPV1TYRSMN1; SMN2NPC1 | |
| SCHEMBL4575016 | 0.85 | HCAR2 (0.55) | CYP1A2TRPV1HCAR2CA12AKR1B10 | |
| SCHEMBL11395099 | 0.84 | CYP1A2 (0.75) | CYP1A2TRPV1HDAC1SMN1; SMN2NPC1 | |
| SCHEMBL798102 | 0.84 | CYP1A2 (0.75) | CYP1A2TRPV1HDAC1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | claimed |
| US-20220259490-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2022-08-18 | — | — | US | claimed |
| WO-2020252075-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-12-17 | — | — | WO | claimed |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-01-28 | — | — | US | claimed |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2017-12-21 | — | — | US | claimed |
| EP-1429768-B1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA (DE) | 2016-11-16 | — | — | EP | claimed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | claimed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | claimed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | claimed |
| US-6919325-B2 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-19 | — | — | US | claimed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1429768-A1 | NOVEL MEDICAMENTS FOR INHALATION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-06-23 | — | — | EP | claimed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | claimed |
| WO-2003024452-A1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-5961875-A | Antifreeze/coolant composition containing cinnamic acid | CCI CO., LTD. (JP) | 1999-10-05 | — | — | US | claimed |
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | disclosed |
| WO-1995004713-A1 | 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS | THE UPJOHN COMPANY (US) | 1995-02-16 | — | — | WO | disclosed |
| US-3966801-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP1A2 2153/4885TRPV1 1/4885HCAR2 89/4885 |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | CA6, CA13, EPCAM | CYP1A2 432/4885TRPV1 1068/4885HCAR2 11/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP1A2 2099/4885TRPV1 1/4885HCAR2 105/4885 |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | ADRB3, ADRB1, HSD3B1 | CYP1A2 357/4885TRPV1 1713/4885HCAR2 1873/4885 |
| US-20170362255-A1 | LIGAND-EXCHANGEABLE NANOPARTICLES AND METHODS OF MAKING THE SAME | CA6, CA13, EPCAM | CYP1A2 432/4885TRPV1 1068/4885HCAR2 11/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | CYP1A2 592/4885TRPV1 578/4885HCAR2 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.